1. Home
  2. MLYS vs UXIN Comparison

MLYS vs UXIN Comparison

Compare MLYS & UXIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • UXIN
  • Stock Information
  • Founded
  • MLYS 2019
  • UXIN 2011
  • Country
  • MLYS United States
  • UXIN China
  • Employees
  • MLYS N/A
  • UXIN N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • UXIN Business Services
  • Sector
  • MLYS Health Care
  • UXIN Consumer Discretionary
  • Exchange
  • MLYS Nasdaq
  • UXIN Nasdaq
  • Market Cap
  • MLYS 890.6M
  • UXIN 764.9M
  • IPO Year
  • MLYS 2023
  • UXIN 2018
  • Fundamental
  • Price
  • MLYS $37.16
  • UXIN $3.61
  • Analyst Decision
  • MLYS Strong Buy
  • UXIN
  • Analyst Count
  • MLYS 6
  • UXIN 0
  • Target Price
  • MLYS $42.60
  • UXIN N/A
  • AVG Volume (30 Days)
  • MLYS 2.6M
  • UXIN 239.4K
  • Earning Date
  • MLYS 11-10-2025
  • UXIN 09-23-2025
  • Dividend Yield
  • MLYS N/A
  • UXIN N/A
  • EPS Growth
  • MLYS N/A
  • UXIN N/A
  • EPS
  • MLYS N/A
  • UXIN 0.94
  • Revenue
  • MLYS N/A
  • UXIN $300,239,165.00
  • Revenue This Year
  • MLYS N/A
  • UXIN N/A
  • Revenue Next Year
  • MLYS N/A
  • UXIN N/A
  • P/E Ratio
  • MLYS N/A
  • UXIN $3.51
  • Revenue Growth
  • MLYS N/A
  • UXIN 58.48
  • 52 Week Low
  • MLYS $8.24
  • UXIN $1.46
  • 52 Week High
  • MLYS $39.20
  • UXIN $7.84
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 86.84
  • UXIN 48.69
  • Support Level
  • MLYS $35.00
  • UXIN $3.21
  • Resistance Level
  • MLYS $15.79
  • UXIN $3.74
  • Average True Range (ATR)
  • MLYS 2.50
  • UXIN 0.35
  • MACD
  • MLYS 2.05
  • UXIN -0.01
  • Stochastic Oscillator
  • MLYS 91.73
  • UXIN 35.04

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

About UXIN Uxin Limited ADS

Uxin Ltd is an investment holding company. Along with its subsidiaries, the firm operates used car e-commerce platforms through its mobile applications and websites. It facilitates used car transaction services and financing solutions offered by third-party financing partners to buyers for their used car purchases. The company generates revenue through sales of the commission of salvage car sales, and interest income from the financial lease. The Group generates its revenues in China, and assets of the company are also located in China Area.

Share on Social Networks: